Pink Sheet is part of Pharma Intelligence UK Limited

This site is operated by Pharma Intelligence UK Limited, a company registered in England and Wales with company number 13787459 whose registered office is 5 Howick Place, London SW1P 1WG. The Pharma Intelligence group is owned by Caerus Topco S.à r.l. and all copyright resides with the group.

This copy is for your personal, non-commercial use. For high-quality copies or electronic reprints for distribution to colleagues or customers, please call +44 (0) 20 3377 3183

Printed By

UsernamePublicRestriction

Industry Laments UK Decision To Go Ahead With ‘Unprecedented’ Sales Repayments

Executive Summary

The UK government has confirmed plans to raise payments made by drug companies in the statutory scheme for branded medicines to 24.4% for 2023, despite clear warnings from industry that the approach is unsustainable and jeopardizes the delivery of the government's ambitions for life sciences in the post-Brexit UK.

You may also be interested in...



Capacity Challenges Prompt NICE To Consider Secondees From Consultancy Firms

England’s health technology assessment institute is exploring solutions to help deal with its increased workload, high staff turnover and challenges in recruiting people with the expertise needed.

UK Industry Attacks Government’s ‘Unsustainable’ Repayment Proposals

Questions are being raised about the credibility of the UK’s voluntary and statutory drug pricing schemes because of uncertainty over the payment percentages companies will have to pay in future.

2021: A Record-Breaking Year For ‘Smart’ Pricing And Access Deals In England

NHS England and Improvement (NHSE&I) agreed 16 pricing and access deals with drug companies in 2021, ten of which can be considered ‘smart.’ The fact that these were achieved against a backdrop of COVID-19 is seen as impressive.

Topics

Latest News
UsernamePublicRestriction

Register

PS146355

Ask The Analyst

Ask the Analyst is free for subscribers.  Submit your question and one of our analysts will be in touch.

Your question has been successfully sent to the email address below and we will get back as soon as possible. my@email.address.

All fields are required.

Please make sure all fields are completed.

Please make sure you have filled out all fields

Please make sure you have filled out all fields

Please enter a valid e-mail address

Please enter a valid Phone Number

Ask your question to our analysts

Cancel